Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: GalXC-plus siRNA therapeutics - Dicerna Pharmaceuticals

Next Previous
X
Search
Drug Profile

Research programme: GalXC-plus siRNA therapeutics - Dicerna Pharmaceuticals

Alternative Names: GalXc-Plus Gen 2; GalXC-Plus-ALDH2; GaLXC-Plus-TUBB3; GaLXC-Plus-ß-tubulin III

Latest Information Update: 29 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dicerna Pharmaceuticals
  • Class Amino sugars; Drug conjugates; Small interfering RNA
  • Mechanism of Action Aldehyde dehydrogenase 2 modulators; Beta III tubulin protein modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Neurological disorders

Most Recent Events

  • 28 Dec 2021 Dicerna Pharmaceuticals has been acquired by Novo Nordisk
  • 09 Nov 2021 Dicerna Pharmaceuticals plans a clinical trial for Neurological disorders in early 2022
  • 30 Mar 2021 Preclinical trials in Neurological disorders in USA (Intracisternal), before March 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top